ECSP14023405A - Anticuerpos anti-baff-anti-il-17 biespecíficos - Google Patents
Anticuerpos anti-baff-anti-il-17 biespecíficosInfo
- Publication number
- ECSP14023405A ECSP14023405A ECIEPI201423405A ECPI201423405A ECSP14023405A EC SP14023405 A ECSP14023405 A EC SP14023405A EC IEPI201423405 A ECIEPI201423405 A EC IEPI201423405A EC PI201423405 A ECPI201423405 A EC PI201423405A EC SP14023405 A ECSP14023405 A EC SP14023405A
- Authority
- EC
- Ecuador
- Prior art keywords
- baff
- bispecific antibodies
- specific antibodies
- sle
- pss
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan anticuerpos biespecíficos que específicamente enlazan el Factor de Activación de células B de la Familia TNF (BAFF) e Interleucina-17A (IL-17) y se caracterizan porque tienen alta afinidad y fuertes propiedades neutralizantes tanto a BAFF como IL-17. Se espera que los anticuerpos biespecíficos de la invención sean útiles en el tratamiento de Nefritis Lúpica (LN), Lupus Eritematoso Sistémico (SLE), Artritis Reumatoide (RA), Psoriasis (Ps), Espondilitis Anquilosante (AS), Artritis Psoriática (PA), Síndrome de Sjögren primario (pSS), o Mieloma Múltiple (MM).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636302P | 2012-04-20 | 2012-04-20 | |
| US201361768747P | 2013-02-25 | 2013-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14023405A true ECSP14023405A (es) | 2015-09-30 |
Family
ID=48539373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201423405A ECSP14023405A (es) | 2012-04-20 | 2014-10-17 | Anticuerpos anti-baff-anti-il-17 biespecíficos |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9359448B2 (es) |
| EP (2) | EP3192809B1 (es) |
| JP (1) | JP6216772B2 (es) |
| KR (1) | KR101673735B1 (es) |
| CN (1) | CN104220455B (es) |
| AP (1) | AP2014008002A0 (es) |
| AR (1) | AR090626A1 (es) |
| AU (1) | AU2013249546B2 (es) |
| BR (1) | BR112014025649A2 (es) |
| CA (1) | CA2869148C (es) |
| CL (1) | CL2014002616A1 (es) |
| CO (1) | CO7160039A2 (es) |
| CR (1) | CR20140466A (es) |
| CY (1) | CY1118824T1 (es) |
| DK (1) | DK2838920T3 (es) |
| DO (1) | DOP2014000234A (es) |
| EA (1) | EA029185B1 (es) |
| EC (1) | ECSP14023405A (es) |
| ES (2) | ES2789474T3 (es) |
| GT (1) | GT201400217A (es) |
| HR (1) | HRP20170468T1 (es) |
| HU (1) | HUE032153T2 (es) |
| IL (1) | IL234965B (es) |
| IN (1) | IN2014MN01876A (es) |
| LT (1) | LT2838920T (es) |
| ME (1) | ME02596B (es) |
| MX (1) | MX367460B (es) |
| MY (1) | MY173282A (es) |
| NZ (1) | NZ630865A (es) |
| PE (1) | PE20142147A1 (es) |
| PH (1) | PH12014502333A1 (es) |
| PL (1) | PL2838920T3 (es) |
| PT (1) | PT2838920T (es) |
| RS (1) | RS55729B1 (es) |
| SG (1) | SG11201406726PA (es) |
| SI (1) | SI2838920T1 (es) |
| TW (1) | TWI585103B (es) |
| WO (1) | WO2013158577A1 (es) |
| ZA (1) | ZA201407272B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| CN105792646B (zh) * | 2013-11-19 | 2018-03-02 | 瑞泽恩制药公司 | 具有人源化的b细胞活化因子基因的非人动物 |
| EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| AU2016297575B2 (en) * | 2015-07-23 | 2021-05-27 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
| CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
| WO2019136311A2 (en) * | 2018-01-05 | 2019-07-11 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
| WO2024140930A1 (en) * | 2022-12-28 | 2024-07-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Bispecific binding protein comprising anti-baff antibody and use thereof |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| WO2025108551A1 (en) | 2023-11-23 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025109206A1 (en) | 2023-11-22 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025222167A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
| WO2025222168A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
| WO2025222170A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| LT2481753T (lt) * | 2005-12-13 | 2018-05-25 | Eli Lilly And Company | Anti-il-17 antikūnai |
| US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en not_active Ceased
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko not_active Expired - Fee Related
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14023405A (es) | Anticuerpos anti-baff-anti-il-17 biespecíficos | |
| MX2015011957A (es) | Anticuerpos biespecificos anti-tnf-anti-il-17. | |
| JOP20140049B1 (ar) | أجسام مضادة ترتبط بـ il-23 | |
| EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
| FR3005570B1 (fr) | Orthese proprioceptive assurant le maintien d'une articulation | |
| MX2015011075A (es) | Peptidos terapeuticos. | |
| EA201590412A1 (ru) | Композиции антител и их применения | |
| MX375889B (es) | Agente ligante de la il-17a y usos del mismo. | |
| UA106900C2 (uk) | Агоністичний dr5-зв'язувальний поліпептид | |
| ECSP14017562A (es) | Formulación de anticuerpo il-17 | |
| EP3473676A4 (en) | ADDITION-CURABLE LIQUID SILICONE RUBBER COMPOSITION | |
| CL2017001757A1 (es) | Proceso para desfosforización de metal fundido durante un proceso de refinación. | |
| MX392703B (es) | Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada. | |
| JP2016525099A5 (ja) | 免疫グロブリンＦｃ断片のＦｃＲｎに対する結合親和力が維持される免疫グロブリンＦｃ結合体 | |
| CL2017002405A1 (es) | Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr. | |
| EP2692793A4 (en) | FORM BODY OF A POLYOLEFIN RESIN COMPOSITION WITH HIGH SCRATCH RESISTANCE | |
| TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| TH1401006266A (th) | แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี | |
| WO2014113431A3 (en) | Methods and compositions for targeting immunoglobulins | |
| MX2015011395A (es) | Bolsas reforzadas. | |
| MA37425B1 (fr) | Anticorps bispécifiques anti-baff-anti-il-17 | |
| TR201104787U (tr) | Çamaşır serme mekanizması. |